Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

The DNA data of more than 15 million customers of DNA testing firm 23andMe is set to be returned to the control of 23andMe co ...

U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as US$80 million into ...